Jul. 31 at 5:34 AM
$PLX So Sanofi USA is looking like the tougher nut to crack. But otherwise I would say positive!
Fabrazyme:
- Overall Fab sales flat at 0.4% CER, when the market should be growing at about 7-8%
- Fab USA up +5.5% CER.
- Fab EU flat at 0% CER, (not growing at 7-8%)
- Fab ROW -9.1% CER with sales at 56M, on par with worst quarter in last 2+ years, this level only seen once Q3 2025 - (definitely not growing at 7-8%)
Replagal:
- EU sales at 10.1B AER = 9B CER. Representing a -7% drop in EU sales QoQ and -13% in EU sales YoY So given Fab sales are flat in EU, then someone is definitely taking up the slack and I don't think all of that is Galafold. (Again market growing at 7-8%)
- ROW/GEM. Harder to compute CER due the number of currencies. But AER is 9.6B, which Gemini calculate approximately as 8.7B CER in that Region. Which indicates a -6.5% drop QoQ.
Overall Replagal's worst quarter since tracking, despite benefitting from the FX tailwind.
